A Novel Therapeutic Strategy of Lipidated Promiscuous Peptide Against Mycobacterium Tuberculosis by Eliciting Th1 and Th17 Immunity of Host

Scientific Reports - United Kingdom
doi 10.1038/srep23917
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Evasion of Innate Immunity by Mycobacterium Tuberculosis: Is Death an Exit Strategy?

Nature Reviews Microbiology
Infectious DiseasesImmunologyMicrobiologyMicrobiology
2010English

Evasion of Innate and Adaptive Immunity by Mycobacterium Tuberculosis

Microbiology spectrum
EcologyImmunologyCell BiologyMicrobiologyMicrobiology GeneticsInfectious DiseasesPhysiology
2014English

Editorial: Emerging Viruses: Host Immunity and Novel Therapeutic Interventions

Frontiers in Immunology
AllergyImmunology
2018English

Role of Glutamine Metabolism in Host Defense Against Mycobacterium Tuberculosis Infection

Journal of Infectious Diseases
Infectious DiseasesAllergyImmunology
2018English

Mycobacterium Tuberculosis PPE60 Antigen Drives Th1/Th17 Responses via Toll-Like Receptor 2–dependent Maturation of Dendritic Cells

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2018English

Modeling the Mycobacterium Tuberculosis Granuloma – The Critical Battlefield in Host Immunity and Disease

Frontiers in Immunology
AllergyImmunology
2013English

Role and Plasticity of Th1 and Th17 Responses in Immunity to Staphylococcus Aureus

Human Vaccines and Immunotherapeutics
MedicineAllergyImmunologyPharmacology
2019English

Novel Human Recombinant Antibodies Against Mycobacterium Tuberculosis Antigen 85B

BMC Biotechnology
Biotechnology
2014English

Protective and Therapeutic Efficacy of Mycobacterium Smegmatis Expressing HBHA-hIL12 Fusion Protein Against Mycobacterium Tuberculosis in Mice

PLoS ONE
Multidisciplinary
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy